Tengion, Inc. (NASDAQ: TNGN) increased 13.24% to $0.770 in the morning hour. ON January 05, 2012, the company announced it has completed the relocation of its corporate headquarters from East Norriton, Pennsylvania to the Company’s existing facility in Winston-Salem, North Carolina.
VIVUS, Inc. (NASDAQ: VVUS) climbed 13.98% to $11.58 in the early hour after the company announced that following recent discussions with Food and Drug Administration (FDA) officials, the company has been asked to remove the Qnexa contraindication for women of childbearing potential contained in the proposed label.
Human Genome Sciences (NASDAQ: HGSI) increased 1.03% to $7.80 in the early hour after the company announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA(R) (belimumab), the first approved drug for systemic lupus in 56 years.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) gained 3.20% to $35.14 in the early hour after the company announced its 2012 business objectives in conjunction with the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Matthew Emmens, Chairman, President and Chief Executive Officer of Vertex, and Jeffrey Leiden, M.D., Ph.D., who will become Vertex’s CEO on February 1, 2012, will discuss these objectives as part of a live presentation, on Monday, January 9 at 11:00 a.m. PT (2:00 p.m. ET).
Sequenom, Inc. (NASDAQ: SQNM) increased 1.19% to $4.26 in the early hour after the company announced highlights of the company’s 2011 performance and accomplishments, as well as preliminary activities and goals for the first part of 2012.Total revenue growth of approximately 23% year-over-year for 2011. Over 21,000 total prenatal and retinal diagnostic tests were billed during the year.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.